Delcath Systems Inc(DCTH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 2400 | EPS (ttm) | 0.01 | Insider Own | 7.49% | Shs Outstand | 34.6M | Perf Week | -0.75% |
| Market Cap | 0.51B | Forward P/E | - | EPS next Y | 67.2% | Insider Trans | - | Shs Float | 32.1M | Perf Month | -8.33% |
| Enterprise Value | 0.41B | PEG | - | EPS next Q | -0.09 | Inst Own | 59.21% | Short Float | 5.87% | Perf Quarter | 19.8% |
| Income | 0.00B | P/S | 5.32 | EPS this Y | -357.14% | Inst Trans | 5.62% | Short Ratio | 4.07 | Perf Half Y | 41.04% |
| Sales | 0.10B | P/B | 4.19 | EPS next 5Y | 37% | ROA | 0.42% | Short Interest | 1.88M | Perf YTD | 44.95% |
| Book/sh | 3.5 | P/C | 5.3 | EPS past 3/5Y | - | ROE | 0.47% | 52W High | -15.96% ($17.42) | Perf Year | 50.62% |
| Cash/sh | 2.76 | P/FCF | 29.01 | Sales past 3/5Y | 215.3% 120.21% | ROIC | 0.43% | 52W Low | 80.3% ($8.12) | Perf 3Y | 346.34% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -76.27% | Gross Margin | 87.05% | Volatility(W/M) | 2.86% 3.52% | Perf 5Y | 31.77% |
| Dividend TTM | - | EV/Sales | 4.34 | Sales Y/Y TTM | 35.85% | Oper. Margin | -1.9% | ATR (14) | 0.49 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 8.95 | EPS Q/Q | 0.15% | Profit Margin | 0.56% | RSI (14) | 43.83 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.83 | Sales Q/Q | 20.6% | SMA20 | -1.93% ($14.93) | Beta | 0.59 | Target Price | $24.5 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/11/9 | SMA50 | -6.85% ($15.72) | Rel Volume | 0.52 | Prev Close | $14.86 |
| Employees | 156 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | 178.56% 10.97% | SMA200 | 18.8% ($12.32) | Avg Volume(3M) | 0.46M | Price | $14.64 |
| IPO | 2001/10/23 | Option/Short | Yes/Yes | Trades | 3600 | Volume | 239,261 | Change | -1.48% |
🩺 Delcath Systems (DCTH) is an interventional oncology medical device company focused on the treatment of primary and metastatic liver cancer. Through its flagship products, the HEPZATO KIT and CHEMOSAT, the company provides a treatment system that delivers high-dose chemotherapy locally to the liver while controlling systemic exposure.
Over the past 1 year, roughly in the middle
16% below its 1-year high.
Traded less than usual. That is 52% of its average volume.
Next earnings report: November 9
10 days to go.
DCTH has a sound balance sheet but weak earning power
Of every $100 in sales, $1.90 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -357.1% this year.
Tap to view numbers
However, it looks expensive
For a company earning $100 a year, you would pay $240,000. Peers typically go for $2,837. Compared with its own 1-year average, it is 216% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +31.8%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 59.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #58 of 142 in the industry
Based on market cap of $508M.
MASS#55 908 Devices Inc $531M PER - 
SGHT#56 Sight Sciences Inc $527M PER - 
SENS#57 Senseonics Holdings Inc $516M PER - DCTH#58 Delcath Systems Inc $508M PER 2400.0 
CERS#59 Cerus Corp $492M PER - 
FAQ
What kind of company is DCTH?
DCTH belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of DCTH?
The market cap of DCTH is approximately $508M, ranking 3,152 within its sector.
What is the P/E ratio of DCTH?
DCTH has a P/E ratio of approximately 2400.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for DCTH?
DCTH has recorded a 52-week high of $17.42 and a low of $8.12.
